VBI Vaccines is a biopharmaceutical company. Co. develops vaccine candidates that mimic the natural presentation of viruses. Co.'s pipeline is comprised of vaccine and immunotherapeutic candidates developed by virus-like particle technologies to target two disease areas, infectious disease and oncology. Co.'s prophylactic candidates are 3-antigen Vaccine for the indication of Hepatitis B (HBV), VBI-1501 for the indication of Cytomegalovirus (CMV), VBI-2901 for the indication of Pan-coronavirus, and VBI-2902 for the indication of COVID-19. Co.'s therapeutic candidates are VBI-2601 for the indication of HBV and VBI-1901 for the indication of Glioblastoma plus other CMV-Associated Cancers. We show 27 historical shares outstanding datapoints in our coverage of VBIV's shares outstanding history.
Understanding the changing numbers of VBIV shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VBIV versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VBIV by allowing them to research VBIV shares outstanding history
as well as any other stock in our coverage universe. |
Free VBIV Email Alerts:
Video: Shares Outstanding Importance
